Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Key facts

Sponsor

Revolution Medicines, Inc.

Principal Investigator

Study Director

Revolution Medicines

Intervention

RMC-6236(drug)

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (20)

• Ironwood Cancer and Research Centers, Chandler, Arizona, United States
• Mayo Clinic Hospital, Phoenix, Arizona, United States
• HonorHealth Research Institute, Scottsdale, Arizona, United States
• UC San Diego Moores Cancer Center, La Jolla, California, United States
• Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles, California, United States
• UCLA Hematology/Oncology- Santa Monica, Los Angeles, California, United States
• University of Colorado Hospital-Anschutz Cancer Pavilion, Aurora, Colorado, United States
• Yale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut, United States
• Mayo Clinic Cancer Center, Jacksonville, Florida, United States
• Moffitt Cancer Center, Tampa, Florida, United States
• The University of Kansas Clinical Research Center, Westwood, Kansas, United States
• The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Dana Farber Cancer Institute, Boston, Massachusetts, United States
• Mayo Clinic, Rochester, Minnesota, United States
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Multilocular cystic renal neoplasm of low malignant potential

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT00898365
  Study of Kidney Tumors in Younger Patients
  Children's Oncology Group

See all trials for Multilocular cystic renal neoplasm of low malignant potential →